New hope for rare, aggressive eye disease: faricimab dosing study launches
NCT ID NCT07187804
First seen Oct 31, 2025 · Last updated May 17, 2026 · Updated 19 times
Summary
This study tests a personalized treatment schedule for faricimab, an eye injection, in 30 people with a severe type of age-related macular degeneration called type 3 macular neovascularization. The goal is to see if a more careful dosing plan can better preserve vision and prevent blindness over 76 weeks. Participants must be over 50 and have a certain level of vision to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (ARMD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kim's Eye Hospital
Seoul, 150-034, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.